Shares of Axonics, Inc. (NASDAQ:AXNX – Get Rating) have been given an average rating of “Buy” by the eight ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among […]
Zacks Investment Research upgraded shares of Axonics (NASDAQ:AXNX – Get Rating) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction […]
Axonics (NASDAQ:AXNX – Get Rating) and Pulmonx (NASDAQ:LUNG – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership. Profitability This table compares Axonics and Pulmonx’s net margins, return on equity […]
Axonics, Inc. (NASDAQ:AXNX – Get Rating) CEO Raymond W. Cohen sold 50,000 shares of the firm’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $52.82, for a total value of $2,641,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]